Cabaletta Bio Inc (CABA)

Currency in USD
1.440
-0.080(-5.26%)
Closed·
After Hours
1.470+0.030(+2.08%)
·
CABA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
Fair Value
Day's Range
1.4301.550
52 wk Range
0.9866.730
Key Statistics
Prev. Close
1.52
Open
1.52
Day's Range
1.43-1.55
52 wk Range
0.986-6.73
Volume
944.36K
Average Volume (3m)
2.16M
1-Year Change
-78.54%
Book Value / Share
2.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CABA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.667
Upside
+987.96%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cabaletta Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Cabaletta Bio Inc Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio Inc SWOT Analysis


Pioneering Therapies
Cabaletta Bio leads in autoimmune CAR-T development, focusing on myositis and scleroderma treatments with potential for durable drug-free remissions
Market Dynamics
Explore CABA's position in the competitive autoimmune treatment landscape, balancing first-mover advantage against intensifying industry rivalry
Financial Tightrope
Delve into CABA's financial challenges, including limited market cap and cash burn, contrasted with its strong liquidity and undervalued status
Future Prospects
Analyst targets range from $6 to $50, reflecting diverse views on CABA's potential in the promising yet uncertain autoimmune CAR-T market
Read full SWOT analysis

Compare CABA to Peers and Sector

Metrics to compare
CABA
Peers
Sector
Relationship
P/E Ratio
−1.0x−2.4x−0.5x
PEG Ratio
0.02−0.020.00
Price/Book
1.1x1.2x2.6x
Price / LTM Sales
-11.6x3.3x
Upside (Analyst Target)
-207.7%45.4%
Fair Value Upside
Unlock33.8%7.7%Unlock

Analyst Ratings

9 Buy
2 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.667
(+987.96% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.71 / -0.6559
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CABA Income Statement

People Also Watch

31.68
BMNR
-8.55%
15.91
SRPT
-3.11%
25.91
CNC
-0.61%
16.380
QBTS
-4.71%
2.56
INMB
-6.23%

FAQ

What Stock Exchange Does Cabaletta Bio Trade On?

Cabaletta Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cabaletta Bio?

The stock symbol for Cabaletta Bio is "CABA."

What Is the Cabaletta Bio Market Cap?

As of today, Cabaletta Bio market cap is 129.52M.

What Is Cabaletta Bio's Earnings Per Share (TTM)?

The Cabaletta Bio EPS (TTM) is -2.57.

When Is the Next Cabaletta Bio Earnings Date?

Cabaletta Bio will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is CABA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cabaletta Bio Stock Split?

Cabaletta Bio has split 0 times.

How Many Employees Does Cabaletta Bio Have?

Cabaletta Bio has 165 employees.

What is the current trading status of Cabaletta Bio (CABA)?

As of 03 Aug 2025, Cabaletta Bio (CABA) is trading at a price of 1.44, with a previous close of 1.52. The stock has fluctuated within a day range of 1.43 to 1.55, while its 52-week range spans from 0.99 to 6.73.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.